Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DL50ZE
|
|||
| Drug Name |
ORY-2001
|
|||
| Synonyms |
Vafidemstat; 1357362-02-7; ORY-2001; Vafidemstat [INN]; LZ82JLT4UP; UNII-LZ82JLT4UP; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; (1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; SCHEMBL528204; CHEMBL4802155; XBBRLCXCBCZIOI-DLBZAZTESA-N; BCP29383; BDBM50594947; AKOS040742807; MS-25100; HY-112623; CS-0058593; ORY 2001; ORY-2001; ORY2001; A930244; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1] | |
| Company |
Oryzon Genomics Boston, MA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H20N4O2
|
|||
| Canonical SMILES |
C1C(C1NCC2=NN=C(O2)N)C3=CC=C(C=C3)OCC4=CC=CC=C4
|
|||
| InChI |
InChI=1S/C19H20N4O2/c20-19-23-22-18(25-19)11-21-17-10-16(17)14-6-8-15(9-7-14)24-12-13-4-2-1-3-5-13/h1-9,16-17,21H,10-12H2,(H2,20,23)/t16-,17+/m0/s1
|
|||
| InChIKey |
XBBRLCXCBCZIOI-DLBZAZTESA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03867253) A Multicentre,Randomised, Double-blind, Placebo-controlled, 3-arm, 24-week Parallel-group Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ORY-2001 in Patients With Mild-moderate Alzheimer's Disease. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Oryzon Genomics Boston, MA | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.